Tickerover
Healthcare

BMRN Stock Analysis

BioMarin Pharmaceutical Inc. · current price $64.64 (-1.03% today)

Setup looks favourable on the available data. Momentum, fundamentals and macro indicators are aligned.
★★★★★
Top Tier
📊

The six-pillar scorecard

Momentum
72
Trending up strong
price trend
Growth
25
Barely growing
sales & profit growth
Quality
91
High quality
profitability & balance sheet
Valuation
75
Looks cheap
is the price fair?
Sentiment
45
Mixed views
analyst & crowd mood
Risk
82
Low risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
RSI zoneRSI zone: 100100Trend strengthTrend strength: 1001001-month momentum1-month momentum: 6262Relative strengthRelative strength: 8585GrowthGrowth: 4848Near 52w highNear 52w high: 100100Analyst consensusAnalyst consensus: 7070
Margin profileWhat survives each step down the income statement.
GrossGross: 51.0%51.0%OperatingOperating: 21.2%21.2%NetNet: 2.1%2.1%Free cash flowFree cash flow: 21.3%21.3%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +25.8% vs estimate+26%2026-062026-03: -16.9% vs estimate-17%2026-032025-12: -17.9% vs estimate-18%2025-122025-09: -64.3% vs estimate-64%2025-09
👁

Hype Check

Reading BMRN’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading BMRN’s filings…

📣

Latest earnings

LAST EARNINGS BioMarin Pharmaceutical Inc. (BMRN)

Latest earnings

EPS
$0.12 vs $0.34 est · -64.3% vs estimate MISS
Revenue
$989.7M · +27.5% YoY
Stock reaction (1M)
+6.8%
Beat streak
1 of last 4 quarters
💰

Valuation

P/E
174.8×
Forward P/E
10.0×
PEG
0.51
Price / Sales
3.7×
Price / Book
2.0×
EV / EBITDA
24.6×
Analyst target
$91.04
Target range
$59.00 – $124.00
Implied upside
+40.8%
🩺

Financial health

Gross margin
51.0%
Operating margin
21.2%
Net margin
2.1%
FCF margin
21.3%
Return on equity
1.2%
Debt / equity
0.66
Revenue growth YoY
+19.9%
EPS growth YoY
-81.3%
📈

Technicals

$49.2652-week range$70.98
RSI (14)
51
50-day MA
$61.61
200-day MA
$57.57
ATR (14)
1.76
Beta
0.23
1-month return
+6.8%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$0.12$0.34-64.3%Miss
2025-12-31$0.46$0.56-17.9%Miss
2026-03-31$0.76$0.91-16.9%Miss
2026-06-30$1.20$0.95+25.8%Beat
Beat 1 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.05%
Beta
0.23
📰

Latest news on BMRN

🔗

Similar stocks in Healthcare

Frequently asked

What is BMRN's Quant Score?

BioMarin Pharmaceutical Inc. (BMRN) currently has a TickerMover Quant Score of 72/100, rated ★★★★★ Top Tier. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is BioMarin Pharmaceutical Inc. (BMRN) a buy?

TickerMover does not give buy or sell recommendations. BMRN scores 72/100 (★★★★★ Top Tier) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is BMRN's score updated?

BMRN's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for BMRN →